Finding. You can grow brain-endothelial extracellular vesicles in a bioreactor for two months and they still carry mitochondria-associated cargo and still put ATP back into oxygen-starved cells. Govindaswamy, Soundara Manickam and colleagues park mouse b.End3 cells in a CELLine AD1000 cartridge, keep viability near 90% for eight weeks, and harvest three- to four-fold more EV protein than flasks. Large and small vesicles look like their batch twins by light scattering and tracking. CD63, CD9 and Arf6 mark the fractions. TOMM20, the mitochondrial outer-membrane import receptor, enriches in large EVs. Proteomics says the bioreactor large-EV mitochondrial cargo signature survives. Both sources restore relative ATP after oxygen-glucose deprivation.
Why this paper matters
Mitochondrial transfer via endothelial vesicles is only a product if you can make it twice. Flask culture is a dead end for that. This preprint is a manufacturing paper with a mitochondrial quality-control assay attached. The quality-control is the reason it is here: TOMM20, a mitochondrial proteome, and an ATP rescue that does not die in the cartridge.
What they actually measured
Side-by-side bioreactor versus batch, two EV sizes, standard EV analytics, TOMM20 blot, proteomics, OGD ATP. Eight-week viability is the process claim.
How to read the score
Low 80s. Real mitochondrial cargo plus a functional ATP number, scale-up not biology-new. Confidence is high for the mouse-line comparison.
Caveats
Relative ATP is not organelle persistence. b.End3 is not a human BBB. Do not call this a stroke therapeutic.
What to do with it
If you make mitochondria-loaded EVs, copy the cartridge and keep TOMM20 plus an OGD ATP assay as release tests. If you came for a new transfer receptor, skip it.